Inactief instrument

Koers pSivida Corp. Nasdaq

Aandelen

Duur

Periode

Stijl

PSivida : Primary Endpoint Met in pSivida's Utilization Study of New Medidur™ Inserter with Smaller Diameter Needle	09-08-16
PSivida : Investigator-Sponsored Phase 2 Study Results Show pSivida's Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve	14-07-16
PSivida : Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe	02-05-16
PSivida : Announces NDA for Medidur™ Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs	28-09-15
PSivida : CEO to Present at Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015	14-09-15

Sector

	Vaira. 1 jan.	Kapi.
VERTEX PHARMACEUTICALS INCORPORATED	-2,31%	103 mld.
REGENERON PHARMACEUTICALS, INC.	+0,56%	95,28 mld.
ARGENX SE	+1,69%	22,15 mld.
BIONTECH SE	-17,37%	21,02 mld.
GENMAB A/S	-9,30%	18,15 mld.
WUXI APPTEC CO., LTD.	-41,01%	16,74 mld.
BEIGENE, LTD.	-14,85%	16,05 mld.
NEUROCRINE BIOSCIENCES, INC.	+3,21%	13,68 mld.
SAREPTA THERAPEUTICS, INC.	+33,54%	12,17 mld.